TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21060160

Group type: EXPERIMENTAL
Intervention: Elimination of cow's milk from the mothers' diet (case group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 114
Study: 18201681

Group type: EXPERIMENTAL
Intervention: Cataract phenotype assignment using serial lens examinations and grading (nuclear, cortical, posterior subcapsular)
Number of subjects: 4628

Group type: EXPERIMENTAL
Intervention: Cataract phenotype based on serial grades
Number of subjects: 4628

Group type: EXPERIMENTAL
Intervention: Cataract phenotype based on last examination alone
Number of subjects: 4628
Study: 17142929

Group type: EXPERIMENTAL
Intervention: Daily oral treatment with 5 mg of folate and 1,500 microg of mecobalamin
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study: 12798401

Group type: EXPERIMENTAL
Intervention: Screening by oral visual inspection by trained health workers at 3-year intervals
Number of subjects: 153708

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 153708

Group type: EXPERIMENTAL
Intervention: Screening intervention
Number of subjects: 153708
Study: 10734618

Group type: EXPERIMENTAL
Intervention: Air-abrasion technique without acid etch
Number of subjects: 84

Group type: COMPARATOR
Intervention: Traditional acid-etch technique
Number of subjects: 84
Study: 8715881

Group type: EXPERIMENTAL
Intervention: Educational program about using five nonpharmacologic pain management techniques
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 54
Study: 1607550

Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide aerosol (ITAA) 220 micrograms/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide aerosol (ITAA) 440 micrograms/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Prednisone 10 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 6382361

Group type: EXPERIMENTAL
Intervention: Moclobemide (mean daily dose 297 mg, treatment duration 2-4 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 29350840

Group type: EXPERIMENTAL
Intervention: Mometasone furoate sinus implants
Number of subjects: 300
Study: 27907074

Group type: EXPERIMENTAL
Intervention: Group-based acceptance and commitment therapy (ACT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 106
Study: 24393423

Group type: EXPERIMENTAL
Intervention: Step count prescription with pedometers, aiming to increase counts by ≥3,000 steps/day over one year, with individualized rate increase.
Number of subjects: 364

Group type: COMPARATOR
Intervention: Usual care with advice to engage in physical activity 30-60 minutes/day.
Number of subjects: 364
Study: 22081474

Group type: EXPERIMENTAL
Intervention: Scheduled infliximab (IFX) at 5 mg/kg intravenously every 8 weeks for 36 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no infliximab)
Number of subjects: 31
Study: 20613538

Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (groups 2 and 3) aiming to maintain the pulse contour-derived cardiac index above 2.5 l m min.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine clinical practice (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol-based anaesthesia (group 3)
Number of subjects: 0
Study: 17992069

Group type: EXPERIMENTAL
Intervention: Health diary program (50 minutes, twice a week for 8 weeks)
Number of subjects: 84
Study: 16191818

Group type: EXPERIMENTAL
Intervention: Bizarre sentences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common sentences
Number of subjects: 0
Study: 11806971

Group type: EXPERIMENTAL
Intervention: 200 mg/m(2) melphalan (arm B)
Number of subjects: 282

Group type: COMPARATOR
Intervention: 8 Gy total body irradiation plus 140 mg/m(2) melphalan (arm A)
Number of subjects: 282
Study: 10357951

Group type: EXPERIMENTAL
Intervention: Early unilateral follicular aspiration (EUFA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Coasting
Number of subjects: 30
Study: 7857101

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR (daily dose 800 mg for 3 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: UFT (daily dose 600 mg for 3 days)
Number of subjects: 21
Study: 1719736

Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch solution (HAES 200/0.62)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch solution (HES 200.000/0.62)
Number of subjects: 10
Study: 7019703

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) plus hydrocortisone
Number of subjects: 96

Group type: COMPARATOR
Intervention: Surgical adrenalectomy
Number of subjects: 96
Study: 30612924

Group type: EXPERIMENTAL
Intervention: Monopolar transurethral resection of the prostate (M-TURP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B-TURP)
Number of subjects: 100
Study: 30673866

Group type: EXPERIMENTAL
Intervention: Fludroxycortide cream (0.125 mg/g) applied three times a day for up to 6 weeks, associated with lip sunscreen (LS) before sun exposure.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Lip sunscreen (LS) only.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fludroxycortide cream (0.125 mg/g) applied three times a day for up to 6 weeks.
Number of subjects: 23
Study: 28624260

Group type: EXPERIMENTAL
Intervention: Telephone coaching of a depression self-care intervention
Number of subjects: 120
Study: 25640772

Group type: EXPERIMENTAL
Intervention: Paired afferent stimulation (PAS) with median nerve stimulation delivered 25ms before TMS at 0.2Hz for 7.5 minutes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Paired afferent stimulation (PAS)
Number of subjects: 28
Study: 23841920

Group type: EXPERIMENTAL
Intervention: 20-week Parents under Pressure (PuP) programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 21185503

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and 80 mg
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Control subjects (not specified treatment)
Number of subjects: 1527
Study: 19552619

Group type: EXPERIMENTAL
Intervention: Linagliptin (10 mg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg three times daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Linagliptin and Metformin co-administration
Number of subjects: 16
Study: 17349494

Group type: EXPERIMENTAL
Intervention: Living with Hope Program (LWHP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 60
Study: 15025737

Group type: EXPERIMENTAL
Intervention: Cetirizine administered orally in various formulations and in single and multiple dosage regimens
Number of subjects: 112
Study: 11965201

Group type: EXPERIMENTAL
Intervention: Rofecoxib (average 24.7 mg daily)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514

Group type: COMPARATOR
Intervention: NSAIDs (ibuprofen 800 mg thrice daily, diclofenac 50 mg thrice daily, nabumetone 1500 mg daily)
Number of subjects: 514
Study: 10023325

Group type: EXPERIMENTAL
Intervention: Bolus cisplatin (arm A)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Continuous infusion cisplatin (arm B)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 97
Study: 7523946

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 529

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 529
Study: 3039826

Group type: EXPERIMENTAL
Intervention: Cellulose (Na‐carboxymethylcellulose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Locust bean gum
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Karaya gum
Number of subjects: 11

Group type: COMPARATOR
Intervention: Basal diet alone
Number of subjects: 11
Study: 29334992

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (supervised exercises, health coaching, activity monitor - Fitbit Flex)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Supervised exercises plus sham coaching and sham activity monitor
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Number of subjects: 160
Study: 26239078

Group type: EXPERIMENTAL
Intervention: Walking skill training program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 25664387

Group type: EXPERIMENTAL
Intervention: Reduced substance use (alcohol)
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Reduced substance use (drugs)
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Access to additional treatment modalities
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Access to prescribed medication
Number of subjects: 835
Study: 24006662

Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation of Shenmen (HT 7)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation of Taiyuan (LU 9)
Number of subjects: 60
Study: 21904120

Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: rMenB with OMV from the Norwegian outbreak strain
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: rMenB alone
Number of subjects: 70
Study: 18556609

Group type: EXPERIMENTAL
Intervention: Randomized encouragement designs where participants are randomly invited to participate in treatment conditions but can choose whether to receive treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative assignment designs where treatment is assigned based on a quantitative measure (e.g., need, merit, risk).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies where treatment assignment is unknown and presumed to be nonrandom.
Number of subjects: 0
Study: 16778647

Group type: EXPERIMENTAL
Intervention: Latanoprost therapy for 1 month
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Brimonidine treatment for nonresponders
Number of subjects: 340

Group type: COMPARATOR
Intervention: Timolol treatment for nonresponders
Number of subjects: 340

Group type: COMPARATOR
Intervention: Pilocarpine treatment for nonresponders
Number of subjects: 340
Study: 12970829

Group type: EXPERIMENTAL
Intervention: Therapy-based studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-based studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methodological quality assessment
Number of subjects: 0
Study: 11573055

Group type: EXPERIMENTAL
Intervention: GRF glue as a topical haemostatic agent
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no GRF glue)
Number of subjects: 40
Study: 9572319

Group type: EXPERIMENTAL
Intervention: Antisecretory drugs in H. pylori-positive peptic ulcer patients taking NSAIDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: H. pylori-negative patients
Number of subjects: 0
Study: 7875101

Group type: EXPERIMENTAL
Intervention: Transvaginal intra-amniotic injection of methotrexate (MTX, 100 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Laparoscopic control into the distended fallopian tube (group A)
Number of subjects: 36
Study: 2851173

Group type: COMPARATOR
Intervention: Chemotherapy (cisplatin and etoposide [VP‐16]) plus radiation therapy (30 + 20 Gy split course)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin and etoposide [VP‐16]) plus radiation therapy (30 + 20 Gy split course) plus lonidamine (LND)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Chemotherapy/radiation (arm A)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Chemotherapy/radiation/LND (arm B)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Chemotherapy/radiation/LND
Number of subjects: 116
Study: 30553135

Group type: EXPERIMENTAL
Intervention: Active management (intentional early delivery 24 hours after second steroid dose)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Expectant management (delivered at 34 weeks, sooner if medically indicated)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Active management
Number of subjects: 139

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 139
Study: 28549471

Group type: EXPERIMENTAL
Intervention: Shared Medical Appointments (SMAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shared Medical Appointments (SMAs) plus Peer-to-Peer (P2P) support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25471468

Group type: EXPERIMENTAL
Intervention: Benzydamine oral rinse
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 23919808

Group type: EXPERIMENTAL
Intervention: Multi-component physical activity intervention including indoor physical activity, recess, daily lessons, and social environment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 21195573

Group type: EXPERIMENTAL
Intervention: 1-octanol as sample diluent in reversed phase liquid chromatography (RPLC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-octanol as sample diluent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indapamide 1.5mg sustained release and 2.5mg immediate release formulations
Number of subjects: 0
Study: 19062240

Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 434

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 434
Study: 17037640

Group type: EXPERIMENTAL
Intervention: Group 1 (anger-related self-rumination)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group 2 (self-related rumination without anger)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Group 3 (non-self-related rumination)
Number of subjects: 36
Study: 14616224

Group type: EXPERIMENTAL
Intervention: Dose increase or augmentation with lithium or desipramine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 101
Study: 10969438

Group type: EXPERIMENTAL
Intervention: Articaine HCl (4% with epinephrine 1:100,000)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lidocaine HCl (2% with epinephrine 1:100,000)
Number of subjects: 70
Study: 9772437

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg orally q12h for 2 days followed by misoprostol 25 micrograms intravaginally q12h
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sodium prasterone sulfate 200 mg intravenously qd for 3 days followed by oxytocin intravenous infusion
Number of subjects: 97
Study: 8380487

Group type: EXPERIMENTAL
Intervention: Milacemide (1,200 mg, single oral dose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31290990

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs) - 14 RCTs (1 ipilimumab, 5 pembrolizumab, 5 nivolumab, 2 atezolizumab, 1 durvalumab)
Number of subjects: 57164

Group type: COMPARATOR
Intervention: Non-immune checkpoint inhibitors - 86 RCTs (74 targeted therapy, 8 chemotherapy, 3 hormone therapy, 1 radiopharmaceutical)
Number of subjects: 57164

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 57164

Group type: COMPARATOR
Intervention: Non-immune checkpoint inhibitors
Number of subjects: 57164

Group type: EXPERIMENTAL
Intervention: Overall agreement between ASCO and ESMO frameworks
Number of subjects: 57164
Study: 28506518

Group type: EXPERIMENTAL
Intervention: Peanuts (56g/d for women, 84g/d for men)
Number of subjects: 61
Study: 26556079

Group type: COMPARATOR
Intervention: Drug therapy (including methylphenidate)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Perceptual motor training (18 sessions over 6 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Combination of drug therapy and perceptual motor training
Number of subjects: 36
Study: 23929374

Group type: EXPERIMENTAL
Intervention: Glass fiber posts with resin-modified glass ionomer cement
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cast gold post and cores with resin-modified glass ionomer cement
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Glass fiber posts with dual-polymerizing resin cement
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cast gold post and cores with dual-polymerizing resin cement
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Glass fiber posts with chemically active autopolymerizing resin cement
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cast gold post and cores with chemically active autopolymerizing resin cement
Number of subjects: 42
Study: 22186428

Group type: EXPERIMENTAL
Intervention: Podcast+Mobile
Number of subjects: 96

Group type: COMPARATOR
Intervention: Podcast
Number of subjects: 96
Study: 18403818

Group type: EXPERIMENTAL
Intervention: Adaptation ability evaluation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dysadaptation evaluation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Emotional attitude evaluation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Behavior correction evaluation
Number of subjects: 120
Study: 16185211

Group type: EXPERIMENTAL
Intervention: Methadone 50 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Methadone 100 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Methadone 150 mg
Number of subjects: 5
Study: 14621086

Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg Turbuhaler
Number of subjects: 18124

Group type: COMPARATOR
Intervention: Salbutamol 200 microg pressurised metered dose inhaler
Number of subjects: 18124
Study: 10376691

Group type: EXPERIMENTAL
Intervention: Ivermectin (150-200 microg/kg body weight)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Lindane (1% topical application)
Number of subjects: 53
Study: 8814696

Group type: EXPERIMENTAL
Intervention: Ann Arbor staging classification
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Stage IV disease with marrow involvement
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Age and sex differences
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Increasing number of lymph node regions involved, constitutional symptoms, splenomegaly, increasing age
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Simple classifications based on lymph node counts and splenomegaly
Number of subjects: 398
Study: 1839379

Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg of TAP-144-SR
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg of TAP-144-SR
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 90 micrograms/kg of TAP-144-SR
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TAP-144-SR (all doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TAP-144-SR (90 micrograms/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TAP-144-SR (doses >30 micrograms/kg)
Number of subjects: 36
Study: 6406436

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31025311

Group type: EXPERIMENTAL
Intervention: SPACE framework
Number of subjects: 0
Study: 30073471

Group type: EXPERIMENTAL
Intervention: ON-OPIOID
Number of subjects: 200

Group type: COMPARATOR
Intervention: OPIOID-NAÏVE
Number of subjects: 200
Study: 27415850

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) consisting of 8 telephone sessions, a patient education book, and a stress management procedure on compact disc.
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual Cardiac Care (UCC)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 193
Study: 24561163

Group type: EXPERIMENTAL
Intervention: Transthoracic impedance sensor with advanced algorithm (SAM algorithm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 40
Study: 21729464

Group type: EXPERIMENTAL
Intervention: Breakfast consumption
Number of subjects: 49

Group type: COMPARATOR
Intervention: No breakfast consumption
Number of subjects: 49
Study: 19711093

Group type: COMPARATOR
Intervention: Prosaccade training at rest neck position (rest training group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prosaccade training at 20 degrees neck flexion position (neck training group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untrained subjects)
Number of subjects: 30
Study: 17183021

Group type: EXPERIMENTAL
Intervention: R allele of PON1 Q192R
Number of subjects: 3266
Study: 14527931

Group type: EXPERIMENTAL
Intervention: Single bolus injection of 50 microm/m2 of G‐CSF (SI)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous injection of 50 microm/m2 of G‐CSF for 24 h (CI)
Number of subjects: 6
Study: 11428246

Group type: EXPERIMENTAL
Intervention: Physical guidance
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nonremoval of the spoon
Number of subjects: 2
Study: 9549021

Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (EMG machine turned off)
Number of subjects: 21
Study: 7509383

Group type: EXPERIMENTAL
Intervention: Mediastinal radiotherapy (RT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Mediastinal radiotherapy plus bleomycin
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 145
Study: 2921725

Group type: EXPERIMENTAL
Intervention: Blue Healon
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clear sodium hyaluronate (Healon)
Number of subjects: 50
Study: 30610516

Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sevoflurane-based anesthesia
Number of subjects: 15
Study: 28602580

Group type: EXPERIMENTAL
Intervention: Infrapopliteal vein bypass (VB)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Plain balloon angioplasty (PBA)
Number of subjects: 104
Study: 25521264

Group type: EXPERIMENTAL
Intervention: Movement Assessment Battery for Children‐2 (MABC‐2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Motion Analysis Laboratory (MAL) data
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both MABC‐2 and MAL data
Number of subjects: 21
Study: 23295073

Group type: EXPERIMENTAL
Intervention: Multimode Comprehensive Tailored Information Package (MCTIP)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Normal information provision
Number of subjects: 103
Study: 21777897

Group type: EXPERIMENTAL
Intervention: 3.9 g/d tranexamic acid
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 1.95 g/d tranexamic acid
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304